Bio-Chemotherapy Of Tumors With Cisplatin And Soluble VEGFR-2

Purpose: The growth and persistence of solid tumors and their metastasis are angiogenesis-dependent. Targeting angiogenesis represents a new strategy for the development of anticancer therapies. Vascular Endothelial Growth Factor is one of the key factors that associated with tumor angiogenesis. In this experiment, we have implemented a treatment regimen of combining plasmid DNA encoding soluble VEGF Recpter-2 and chemotherapeutic drug Cisplatin to treat the H22 hepatoma and Meth A fibrosarcoma in BALB/c mice in order to explore the possibility of Bio-Chemotherapeutic strategy for cancer. We use low-dose cisplatin to avoid the obvious toxic side effects and obstruct the development of drug resistance by tumor cells. Materials and Methods: In this experiment, H22 hepatoma model and Meth A fibrosarcoma model were established in 6-8 weeks BALB/c mice and then treated with either soluble VEGFR-2(100μg i.m. every three days for four times), Cisplatin(2mg/Kg, i.p. once a week for two weeks), both agents together or NS. Then observe the volume of tumor, suvival rate of mice,side effects of chemotherapy as well as make immunohistochemical analysis of tumor section.Results: The combination therapy of soluble VEGFR-2 and cisplatin results in significant antitumor activities. Its inhibition of tumor growth is efficient (P<0.05), arid the survival time is much longer compared with control group. Angiogenesis was apparently inhibited in tumor by immunohistochemical analysis(CD31 staining), and increased apoptotic cells were found within the tumor tissues from the mice treated with plasmid DNA encoding soluble VEGFR-2.Conclusion: The present findings provide evidence of the efficient antitumor effects of the combination therapy with plasmid DNA encoding soluble VEGFR-2 and cisplatin, which may be of importance for the further exploration of the application of combination of antiangiogenic gene therapy with chemotherapy.